ERBB2 and retinopathy of prematurity: In conclusion, the results of the ROP Study suggest that in patients who received long-term H therapy for HER2-positive disease (≥ 5 years and ≥ 3 years for patients with HER2-positive locally advanced/metastatic breast and gastric/GEJ cancer, respectively), treatment with H had an acceptable safety profile and was well tolerated; further investigation and reporting of long-term H therapy would be valuable.